Cervical cancer vaccine route of administration
Clinical efficacy for the hpv4 against cervical disease was determined in two double-blind studies against placebo. HPV2 efficacy was evaluated in two randomized, double-blind, controlled clinical trials in women aged 15 to 25 years. high efficacy in women without evidence of infection with HPV vaccine types. No evidence of effectiveness against the diseases caused by vaccine types with which participants were infected at the time of vaccination. Prior infection with an HPV type does not diminish the effectiveness of the vaccine against the other HPV types in the vaccine. Participants infected by one or more HPV types of a vaccine before immunization were protected against disease caused by other types of vaccines. Prior infection with an HPV type does not diminish the effectiveness of the vaccine against the other HPV types in the vaccine.
The duration of vaccine protection, we do not know. For both vaccines a subset of participants were followed for more than 60 months with no evidence of waning protection. Study populations continue to monitor for any evidence of waning immunity. ACIP recommends vaccination of women with HPV2 hpv4 or for the prevention of cancers and precancerous lesions of the cervix. Hpv4 is also recommended for the prevention of genital warts.
ACIP recommends routine vaccination at age 11 or 12 years with hpv4 or HPV2 for women and for men hpv4. ACIP recommends routine vaccination at age 11 or 12 years with hpv4 or HPV2 hpv for women and 4 men. The vaccination series can be started from the age of 9 years. Vaccination also recommended for women 13 to 26 years. Vaccination also recommended for men 13 to 21 years.
Men aged 22-26 years can be vaccinated. Hpv4 and HPV2 are administered each in a series of 3 doses. The second dose is given 1 to 2 months after the first dose and the third dose of 6 months after the first dose. Vaccination is also recommended for women aged 13-26 years and men aged 13 to 21, who are not vaccinated or have not completed the 3-dose series.
Men aged 22-26 years without these risk factors can be vaccinated as well. HPV2 is neither authorized nor recommended for men. Sexually active people who are not infected with one type of vaccine will receive all the benefits of vaccination. Vaccination will provide fewer advantages people if they have already been infected by one or more of the types of vaccine. However, it is not possible for a clinician to assess the extent to which sexually active people could benefit from vaccination and the risk of HPV infection may continue as long as the sexually active.
Pap test or screening for HPV DNA or antibodies hpv are not recommended before vaccination at any age. Two HPV vaccines are administered in a series of three doses of intramuscular injections. The second and third doses should be administered 1 to 2 and 6 months after the first dose. The third dose should take the first dose at least 24 weeks. The third dose does not need to be repeated as long as it was administered at least 16 weeks after the first dose and at least 12 weeks after the second dose. An accelerated timetable for the vaccine against HPV is not recommended.
Accelerated using minimum interval schedule is not recommended. Series does not need to be restarted if the timing is interrupted. assessments prevaccination not recommended. No therapeutic effect on HPV infection, genital warts, cervical lesions. There is no maximum interval between doses. If the vaccine against HPV schedule is interrupted, the vaccine series does not need to be restarted.
If the series is interrupted after the first dose, the second dose should be administered as soon as possible, and the second and third doses should be separated by an interval of at least 12 weeks. Whenever possible, the same vaccine should be used for the entire series of immunizations. No studies focus on the interchangeability of vaccines against HPV. However, if the vaccine supplier does not know or have the vaccine administered product previously or vaccine against HPV can be used to complete the series to provide protection against HPV 16 and 18.